Axsome Therapeutics, Inc. (AXSM)
207.15
+1.67
(+0.81%)
USD |
NASDAQ |
Aug 26, 16:00
207.00
-0.15
(-0.07%)
Pre-Market: 20:00
Axsome Therapeutics Gross Profit Margin (Quarterly) : 92.47% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 92.47% |
| March 31, 2026 | 91.06% |
| December 31, 2025 | 92.55% |
| September 30, 2025 | 91.62% |
| June 30, 2025 | 89.62% |
| March 31, 2025 | 90.18% |
| December 31, 2024 | 89.40% |
| September 30, 2024 | 89.98% |
| June 30, 2024 | 88.63% |
| Date | Value |
|---|---|
| March 31, 2024 | 89.16% |
| December 31, 2023 | 87.25% |
| September 30, 2023 | 85.09% |
| June 30, 2023 | 85.55% |
| March 31, 2023 | 89.92% |
| December 31, 2022 | 82.33% |
| September 30, 2022 | 76.92% |
| June 30, 2022 | 74.43% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Eli Lilly & Co. | 85.78% |
| Liquidia Corp. | 93.10% |
| Filana Therapeutics, Inc. | -- |
| CorMedix, Inc. | 75.66% |
| Eloxx Pharmaceuticals, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -256.9% |
| Return on Assets | -27.58% |
| Return on Invested Capital | -64.85% |
| Profit Margin (Quarterly) | -23.50% |
| Operating Margin (Quarterly) | -23.42% |
| Return on Net Operating Assets | -57.00% |